Scientists uncover secrets of gut hormones in Pancreas-Free patients
NCT ID NCT06895408
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed study looked at how two gut hormones, GIP and GLP-1, affect the body in people who have had their pancreas removed. Researchers gave these hormones alone and together to 12 participants to measure changes in blood sugar, fat, and bone markers. The goal was to understand why a new combination drug for diabetes and obesity works better than GLP-1 alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1)
- What this could lead to
- If successful, this research could help explain why a new class of combination drugs works better than current GLP-1 treatments for diabetes and obesity.
- What could go wrong
- This is a small, early-stage study with only 12 participants who have had their pancreas removed, so results may not apply to the general population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
12 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
30 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Total pancreatectomy * Caucasians between 30-75 years of age * Blood haemoglobin \>7.0 mmol/l for males and \>6.5 mmol/l for females Exclusion Criteria: * Pancreatectomy within the last 3 months * Ongoing chemotherapy or chemotherapy within the last 3 months * Treatment with GLP-1 receptor agonists within the last 3 months * Renal impairment (estimated by estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2) and/or albuminuria * Calcium related disease, hypo-/hyperthyroidism * Known significant liver disease, plasma alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 × normal value or INR (The international normalised ratio based on prothrombin time) outside the normal range * Severe arteriosclerotic heart disease or heart failure (New York Heart Association (NYHA) group III or IV) * Pregnancy and/or breastfeeding * Use of more than 14 units of alcohol per week or abuse of narcotics * Any condition that the investigator feels would interfere with trial participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatectomy; hyperglycemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, 2900, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.